CN106138164A - A kind of compound Chinese medicinal preparation with Adjust-blood lipid function - Google Patents
A kind of compound Chinese medicinal preparation with Adjust-blood lipid function Download PDFInfo
- Publication number
- CN106138164A CN106138164A CN201510127377.8A CN201510127377A CN106138164A CN 106138164 A CN106138164 A CN 106138164A CN 201510127377 A CN201510127377 A CN 201510127377A CN 106138164 A CN106138164 A CN 106138164A
- Authority
- CN
- China
- Prior art keywords
- food
- compound
- medicinal preparation
- chinese medicinal
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 239000008280 blood Substances 0.000 title claims abstract description 24
- 125000003473 lipid group Chemical group 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 30
- 150000002632 lipids Chemical group 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 19
- 229930187479 gypenoside Natural products 0.000 claims abstract description 19
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 238000004040 coloring Methods 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 11
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241001065361 Gynostemma Species 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 16
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 11
- 208000026435 phlegm Diseases 0.000 abstract description 11
- 229930182470 glycoside Natural products 0.000 abstract description 10
- 150000002338 glycosides Chemical class 0.000 abstract description 10
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 238000011866 long-term treatment Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 description 17
- 241000700159 Rattus Species 0.000 description 14
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 7
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 101000963440 Bacillus subtilis (strain 168) Biotin carboxylase 1 Proteins 0.000 description 4
- 102100021334 Bcl-2-related protein A1 Human genes 0.000 description 4
- 101150073133 Cpt1a gene Proteins 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 102000023984 PPAR alpha Human genes 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 3
- -1 Gypenosides compound Chemical class 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 102000012141 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 3
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 229920000080 bile acid sequestrant Polymers 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000639924 Aspergillaceae Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 244000113306 Monascus purpureus Species 0.000 description 1
- 235000002322 Monascus purpureus Nutrition 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 229930186669 gynosaponin Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940057059 monascus purpureus Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of compound Chinese medicinal preparation with Adjust-blood lipid function, be with dehumidifying eliminate the phlegm, red colouring agent for food, also used as a Chinese medicine promoting blood circulation and removing blood stasis, warm in nature with can qi and activate blood circulation, eliminating the phlegm silt, gynostemma pentaphylla cool in nature carry out prescription, the activity of the two is made to produce collaborative, strengthen its be in harmonious proportion, regulate the flow of vital energy, reduce phlegm, the effect of the stasis of blood of dispelling, thus strengthen the effect of its reducing blood lipid.In order to improve the drug effect of compound Chinese medicinal preparation further, can be selected for fermented pharmaceutical functional red colouring agent for food, also used as a Chinese medicine and Gypenosides carries out prescription and uses pharmaceutically acceptable auxiliary material to be prepared as oral preparations.Zoopery shows, compound preparation of the present invention combination has well synergy, and compared with the Zhibituo Tabiet being used alone red colouring agent for food, also used as a Chinese medicine containing same dose or the Herb Gynostemmae Pentaphylli total glycosides tablet being used alone Gypenosides containing same dose, compound preparation result for the treatment of is more notable.In addition, compound Chinese medicinal preparation of the present invention has no toxic and side effect, better tolerance, cheap, applicable long-term treatment uses.
Description
Technical field
The invention belongs to field of medicaments, particularly to a kind of by the compound preparation that pharmaceutical functional red colouring agent for food, also used as a Chinese medicine, medicinal Gypenosides are active component, be mainly used in the conciliation of blood fat and the treatment of NASH.
Background technology
High fat of blood is also known as hyperlipidemia, show as dyslipidemia, it is a kind of common metabolic syndrome with lipid disorders as feature, its feature includes hypercholesterolemia, hypertriglyceridemia and familial combined hyperlipidemiam, it can cause some other metabolism class diseases, such as atherosclerotic, NASH, angiocardiopathy, diabetes, insulin resistance and obesity etc..Can be caused coronary artery disease and cerebral apoplexy by the atherosclerotic caused by dyslipidemia, this is to cause one of the elderly's main causes of death.Nearly ten years, with the change that Chinese's life style and diet are arranged in pairs or groups, angiocardiopathy has become as first-class killer.Show according to the data of modern medicine diseases monitoring, the whole world is died from more than nearly 4000 people of number of the cardiovascular and cerebrovascular disease that hyperlipemia causes every day, myocardial infarction, diabetes, apoplexy, hemiplegia, cerebral infarction that China causes because of hyperlipemia every year, disable, lethal number is in ascendant trend year by year, China dyslipidemia patient up to 1.6 hundred million, and every day is still with the speed increase of ten thousand people.Relevant statistics shows, the incidence of disease of normal population high fat of blood is 20-40%, and convergence becomes younger.
It is currently used for treating drug main nicotinic acid to be had class, acyl-coenzyme a cholesterol acyltransferase depressant, bile acid-binding resin, fibrates and the Statins etc. of hyperlipemia.Fibrates is the part of a class peroxisome proliferator activated receptor alpha (PPAR-α), is the drug of first choice of fall TG, also has the effect of very strong rising HDL-C simultaneously；Statins is also HMG-CoA reductase inhibitor, can effectively suppress the activity of key enzyme HMG-CoA reductase in Biosynthesis of cholesterol, thus reduce TC, LDL-C, play the effect of regulation human body dyslipidemia, during the heavy dose of application of statins, there will be the temporary responses such as myalgia, gastrointestinal reaction, headache according to data to some patients；And bile acid-binding resin class medicinal application dosage is big, there are again off-odor and certain excitant, may have the bad reactions such as nauseating, constipation, abdominal distension, poor appetite after medication, just can fade away after general two weeks；The application of fibrate and nicotinic acid can produce gastrointestinal discomfort, cause lesions of liver and kidney.
NASH (NAFLD) refers to the adipose metabolism function generation obstacle being caused in the case of alcohol-free abuse by many reasons, lipid material dynamic equilibrium is lacked of proper care, cause the accumulation of too much lipid (predominantly triglycerides) in the simple steatosis of liver and liver, if state of an illness deterioration further can become fat hepatitis, cirrhosis or hepatonecrosis.General long-term hyperlipemic patients is all with fatty liver in various degree, and the incidence of disease of disease of cardiovascular system is also high than normal person.
Traditional Chinese medicine or Chinese medical extract have medicament sources to be enriched, and security is high, and side effect is little, cheap and applicable long-term treatment.Therefore research and development have the compound Chinese medicinal preparation of hypolipemic function and have good clinical value.
Content of the invention
It is an object of the invention to provide a kind of compound Chinese medicinal preparation with Adjust-blood lipid function.
Traditional Chinese medical theory is studied for a long period of time by the present invention based on inventor, it is believed that the pathological essence of high fat of blood and (or) NASH is the blood phlegm second of the three ten-day periods of the hot season, and the turbid Cheng Ze of phlegm is because of in visceral dysfunction.I.e. phlegm and blood stasis is hyperlipidemia or the inevitable outcome of NASH development, and it is the hinge of hyperlipidemia deterioration of a case that passages through which vital energy circulates is got involved.It is therefore proposed that dispel based on the stasis of blood with regulating qi-flowing for eliminating phlegm, coordinate the complex treatment hyperlipemia principle rationally taken good care of.
Red colouring agent for food, also used as a Chinese medicine, another name: monascus, monascus purpureus, red rice, red wine dregs.Derive from the red yeast rice that Aspergillaceae fungi monascus parpureus Went colonizes on polished rice, be used as medicine with mycelium and spore.Pharmaceutical functional red colouring agent for food, also used as a Chinese medicine is with high-quality pollution-free non-transgenic rice as primary raw material, utilizes the high-tech fermented product of a kind of pure natural that modern biotechnology fermentation engineering refines, its property sugariness temperature, enter liver, spleen, large intestine channel, have and help digestion and stomach, promoting blood circulation and stopping pain, invigorating the spleen, effect of dry stomach.For retention of food and drink, the diseases such as chest diaphragm is full vexed, indigestion.
Gynostemma pentaphylla, calls seven leaf courages, Herba Gynostemmatis, the public arched end, raw, the Herba Gynostemmatis that lands.Herb for cucurbitaceous plant gynostemma pentaphylla.Bitter, micro-sweet, cool in nature.Return lung；Spleen；Kidney channel.Effect: replenish qi to invigorate the spleen, preventing phlegm from forming and stopping coughing, clearing heat and detoxicating.Clinic is mainly used in the treatment of Aged People With Hyperlipoidemia, virus hepatitis, chronic gastroenteritis, chronic bronchitis.The main effective ingredient of gynostemma pentaphylla is gynosaponin, gynostemma pentaphylla glucoside (polysaccharide), water-soluble amino acids, flavonoids, multivitamin, trace element, mineral matter etc..From gynostemma pentaphyllum herb, extractible more than 80 kinds of saponins are referred to as Gypenosides, are respectively provided with the dammarane type structure of tetracyclic triterpene, and glycosyl is compound sugar, wherein four kinds and Ginsenoside Rb1、—Rb3、—R4、—F2Identical, it is a kind of of great value senior Chinese medicine.
The present invention is eliminated the phlegm to dehumidify, red colouring agent for food, also used as a Chinese medicine promoting blood circulation and removing blood stasis, warm in nature with can qi and activate blood circulation, eliminating the phlegm become silted up, gynostemma pentaphylla cool in nature carry out prescription, the activity of the two is made to produce collaborative, strengthen its be in harmonious proportion, regulate the flow of vital energy, reduce phlegm, the effect of the stasis of blood of dispelling, thus strengthen the effect of its reducing blood lipid.
In order to improve the drug effect of compound Chinese medicinal preparation further, the present invention can be selected for fermented pharmaceutical functional red colouring agent for food, also used as a Chinese medicine and Gypenosides carries out prescription, the two carries out dispensing by the weight ratio of 1.8:1～16.8:1, uses pharmaceutically acceptable auxiliary material to be prepared as oral preparations (such as granule, tablet, capsule, pill, powder, oral liquid).
The result for the treatment of merging NASH SD rat model below by the hyperlipidemia induced red colouring agent for food, also used as a Chinese medicine Gypenosides compound preparation of the present invention to high fat diet through animal experiment illustrates.
1st, experiment material
(1) animal: SD male rat, cleaning grade, body weight (200 ± 10) g, provided by Lanzhou University's Medical experimental center；
(2) main agents and medicine: functional Monascus powder is purchased from Zhejiang Sanhe Bioengineering Co., Ltd., lot number: 2014012301, Gypenosides is purchased from Ankang Chia Tai Pharmaceutical Co., Ltd., lot number: 20130704, Zhibituo Tabiet is purchased from Chengdu Diao 9 Wang pharmaceutical factory, lot number: 1310005, Herb Gynostemmae Pentaphylli total glycosides tablet is purchased from Guangzhou Baiyunshan Heji Huangpu Chinese Medicine Co., Ltd., lot number: G3A001；Basal feed and high lipid food (75% basal feed+9% lard+5.5% yolk powder+7.5% sucrose+2.5% cholesterol+0.3% sodium taurocholate+0.2% propylthiouracil) are pulled together feed corporation,Ltd purchased from Beijing Australia of section；TC, TG, LDL-C, HDL-C measure kit and are purchased from Sichuan mikey Biological Co., Ltd., and lot number is respectively as follows: the 1213051st, the 1213061st, the 1013051st, 0913071, and RT-PCR kit and primer are purchased from precious bioengineering (Dalian) Co., Ltd.RNAiso Plus (Total RNA extracts reagent) lot number: AK9502, Prime ScriptTMRT
Master Mix (Perfect Real Time Reverse Transcription) lot number: AK3002, SYBR Premix Ex Taq TM II (TliRNaseH Plus PCR reagent) lot number: AK5702.
2nd, experimental technique
(1) choosing the age-matched SD male cleaning grade rat that 40 same environment are raised, body weight (200 ± 10) g, the feeding environment temperature of rat is 23 ± 1 DEG C, relative humidity 55% ± 5%, and carries out the light dark cycle of a 12h.All rats are randomly divided into 2 groups after basal feed is fed one week, it is respectively Normal group (8) and model group (32), Normal group continues to give basal feed and after model group gives high lipid food 30 days, all rats by after etherization through eye socket blood sampling, measure serum lipids；From the beginning of the 31st day, model group is randomly divided into 4 groups (often organizing 8), respectively model control group, Zhibituo Tabiet treatment group, Herb Gynostemmae Pentaphylli total glycosides tablet treatment group, compound preparation treatment group.Four groups of rats continue to feed high lipid food, three administration group medicines all give same level with respective concentration 5ml/kg gavage, with dose, (Zhibituo Tabiet treatment group 187.5mg/kg is identical with effective red colouring agent for food, also used as a Chinese medicine dosage that compound preparation treatment group 93.9mg/kg gives, Herb Gynostemmae Pentaphylli total glycosides tablet treatment group 156.7mg/kg is identical with effective Gypenosides dosage that compound preparation treatment group 93.9mg/kg gives) corresponding medicine, Normal group and model control group give corresponding dosage distilled water.After being administered 37 days, water 12h, extracting vein blood are can't help in fasting, measure serum lipids, 10% chloraldurate intraperitoneal anesthesia, take liver.
(2) all rats are after obtaining liver, after the rinsing of liver middle period physiological saline, be soaked into immediately pH=7.4 PBS preparation 10% formalin in, place after one week for 4 DEG C, FFPE carries out histotomy, checks liver organization pathological change after HE dyeing.
null(3) the remaining liver of all rats need not rinse，It is immediately placed in and passed through that 0.1%DEPC is water-treated and in the centrifuge tube of autoclaved 15ml，-80 DEG C of storages，Within 30 days, the liver organization of storage is done real-time quantitative PCR (RT-PCR)，By kit, operation is described，About the relative expression of the mRNA corresponding to the enzyme of lipid synthesis and metabolism in detection rat liver，Do internal reference with β-actin，Hydroxyl first glutaryl CoA-reductase (HMGR)、Fatty acid synthetase (FAS)、Acetyl-CoA carboxylase 1(ACC-1)、Sterol responds original paper Binding Protein 1 c(SREBP-1c)、Peroxisome proliferator-activated receptor alpha (PPAR-α) and carnitine palmityl transferase 1(CPT-1) synthetic primer sequence as shown in table 1.
(4) spss16.0 software kit is used in data statistics and mapping；Measurement data withRepresent, carry out comparing two-by-two between one-way analysis of variance and group.
3rd, experimental result
The measurement result of 3.1 serum lipids
Being administered front 4 group model groups serum TG, LDL-C and TC concentration compared with Normal group significantly to raise (P < 0.01), HDL-C concentration significantly reduces (P < 0.01), illustrates that 4 group model group high blood lipid models model successfully；Three groups of administration group result for the treatment of highly significant (P < 0.01) compared with model control group after administration；It is more notable (P < 0.05, P < 0.01) that two groups of administration groups of compound preparation treatment group and other compare result for the treatment of, is shown in Table 2.
3.2 pathology of hepar analyses
To display after 5 groups of rat liver section HE dyeing such as Fig. 1, model control group and Normal group, there is substantial amounts of circular fat vacuole, illustrate that nonalcoholic fatty liver model is built successfully, and three administration groups also have fat drop pathology (having a small amount of circular fat vacuole) in various degree, compound preparation group liver organization more levels off to the Normal group amount of fat vacuole (circular considerably less), and prompting compound preparation group has prevention or therapeutic action to rat nonalcoholic fatty liver.
3.3 livers are about the expression of lipid synthesis and metabolism mRNA
The expression of Normal group (NC) is set to 1 by each mRNA relatively, and the height of other groups changes based on this.Fig. 2 display model control group (MC) is compared with Normal group (NC), mRNA hydroxyl first glutaryl CoA-reductase (HMGR) about lipid synthesis, fatty acid synthetase (FAS), acetyl-CoA carboxylase 1(ACC-1) and sterol response original paper Binding Protein 1 c(SREBP-1c) expression all significantly raised (P < 0.01), mRNA peroxisome proliferator-activated receptor alpha (PPAR-α) and carnitine palmityl transferase 1(CPT-1 about lipid-metabolism) expression all substantially reduce (P < 0.01), prompting rat synzyme of lipid after giving high lipid food is activated and has raised, metabolic enzyme is suppressed substantially to be lowered.The expression of three administration groups mRNA mrna expression about lipid synthesis compared with model group all significantly reduces (P < 0.01), and the mrna expression about lipid-metabolism significantly raises (P < 0.01)；Compared with Herb Gynostemmae Pentaphylli total glycosides tablet treatment group (JT), HMGR and ACC-1 is lowered and the rise effect more significantly (P < 0.01) to CPT-1 by compound preparation group (HG)；Compared with Zhibituo Tabiet group (ZT), FAS, ACC-1 and SREBP-1c are lowered by compound preparation group (HG) and the rise effect to PPAR-α and CPT-1 is more notable (P < 0.01).Prompting is compared with Herb Gynostemmae Pentaphylli total glycosides tablet and Zhibituo Tabiet, and compound preparation has higher targeting regulation effect to some about the enzyme of lipid synthesis or metabolism.
Above-mentioned results of animal shows, compound preparation of the present invention can significantly reduce rat model serum TC, TG and LDL-C, notable elevating HDL-C, can effectively prevent and treat the deposition that the liver fat of rat model drips, above-mentioned effect is all significantly better than the Herb Gynostemmae Pentaphylli total glycosides tablet (Guangzhou Baiyunshan Heji Huangpu Chinese Medicine Co., Ltd.) being used alone the Zhibituo Tabiet (Chengdu Diao 9 Wang pharmaceutical factory) of the amount of herbal leaven containing equal red or being used alone Gypenosides containing same dose, thus has well synergy.Experiment also shows, to in liver, some also have preferable regulation effect about the enzyme of lipid synthesis and metabolism to compound Chinese medicinal preparation of the present invention, blood fat can be effectively promoted and recover normal, reverse the deposition that liver fat drips, make pathologic liver organized renewing normal, therefore can be used for treating and preventing hyperlipidemia, NASH or various chronic liver disease hepatic injuries etc..In addition, compound Chinese medicinal preparation of the present invention has no toxic and side effect, better tolerance, cheap, applicable long-term treatment uses.
Brief description
Fig. 1 is SD liver tissues of rats pathological observation result (HE dyeing × 400), wherein NC: Normal group, MC: model control group, ZT: Zhibituo Tabiet treatment group, JT: Herb Gynostemmae Pentaphylli total glycosides tablet treatment group, HG: compound red leaven Gypenosides preparation for treating group, RFV: circular fat cavity (Round Fat Void)
Fig. 2 is the statistical chart in SD rat liver tissue about fat metabolism and the mRNA relative expression quantity of synzyme, wherein NC: Normal group, MC: model control group, ZT: Zhibituo Tabiet treatment group, JT: Herb Gynostemmae Pentaphylli total glycosides tablet treatment group, HG: compound red leaven Gypenosides preparation for treating group.**P < 0.01, other groups vs Normal group (n=8)；##P < 0.01, administration group vs model control group (n=8)；▲P < 0.05,▲▲P < 0.01, Zhibituo Tabiet treatment group, Herb Gynostemmae Pentaphylli total glycosides tablet treatment group vs compound preparation treatment group (n=8).
Detailed description of the invention
Illustrate below by preparation and usage, consumption to compound Chinese medicinal preparation of the present invention for the specific embodiment.
The preparation of embodiment the 1st, granules medicine
Weigh by the weight ratio of 1.8:1 and take functional Monascus powder and Gypenosides, prepare the common process of granule with pharmacy and auxiliary material is prepared from；Specification: 5g/ bag；
Usage and dosage: three times a day, each serving 5-10g；It within 90 days, is a course for the treatment of, take 2-3 the course for the treatment of according to individual's concrete condition.
The preparation of embodiment the 2nd, capsule medicine
Weigh by the weight ratio of 5:1 and take functional Monascus powder and Gypenosides, prepare the common process of capsule with pharmacy and auxiliary material is prepared from；Specification: 200mg/ grain；
Usage and dosage: three times a day, each serving 2-3 grain；It within 90 days, is a course for the treatment of, take 2-3 the course for the treatment of according to individual's concrete condition.
The preparation of embodiment the 3rd, tablet medicine
Weigh by the weight ratio of 10:1 and take functional Monascus powder and Gypenosides, prepare the common process of tablet with pharmacy and auxiliary material is prepared from；Specification: 350mg/ piece；
Usage and dosage: every day 2 times, each serving 350-700mg；It within 90 days, is a course for the treatment of, take 2-3 the course for the treatment of according to individual's concrete condition.
The preparation of embodiment the 4th, pill medicine
Weigh by the weight ratio of 15:1 and take functional Monascus powder and Gypenosides, prepare the common process of granule with pharmacy and auxiliary material is prepared from；Specification: 200mg/ grain；
Usage and dosage: three times a day, each serving 2-3 grain；It within 90 days, is a course for the treatment of, take 2-3 the course for the treatment of according to individual's concrete condition.
The preparation of embodiment the 5th, oral liquid
Preparation technology: prepare the common process of oral liquid by pharmacy and auxiliary material is prepared from；Specification: every bottle of 10ml；
Weigh by the weight ratio of 18:1 and take functional Monascus powder and Gypenosides, prepare the common process of granule with pharmacy and auxiliary material is prepared from；Specification: 10ml/ bottle；
Usage and dosage: three times a day, each serving 10-20ml；It within 90 days, is a course for the treatment of, take 2-3 the course for the treatment of according to individual's concrete condition.
In above-described embodiment, functional Monascus can be prepared by Monascus ruber fermentation or business procurement obtains；Gypenosides can be extracted by seven leaves or five leaf gynostemma pentaphyllum herbs or aerial part and obtain or commercially available.
Claims (4)
1. there is a compound Chinese medicinal preparation for Adjust-blood lipid function, be with red colouring agent for food, also used as a Chinese medicine, gynostemma pentaphylla as raw material, the oral preparations being prepared as by pharmaceutically acceptable auxiliary material.
2. there is the compound Chinese medicinal preparation of Adjust-blood lipid function as claimed in claim 1, it is characterised in that: described red colouring agent for food, also used as a Chinese medicine is pharmaceutical functional red colouring agent for food, also used as a Chinese medicine, and gynostemma pentaphylla is Gypenosides.
3. there is the compound Chinese medicinal preparation of Adjust-blood lipid function as claimed in claim 2, it is characterised in that: pharmaceutical functional red colouring agent for food, also used as a Chinese medicine carries out dispensing with medicinal Gypenosides with the weight ratio of 1.8:1～18:1.
4. there is as described in claim 1-3 the compound Chinese medicinal preparation of Adjust-blood lipid function, it is characterised in that: described oral preparations is granule, tablet, capsule, pill, powder, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510127377.8A CN106138164A (en) | 2015-03-23 | 2015-03-23 | A kind of compound Chinese medicinal preparation with Adjust-blood lipid function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510127377.8A CN106138164A (en) | 2015-03-23 | 2015-03-23 | A kind of compound Chinese medicinal preparation with Adjust-blood lipid function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106138164A true CN106138164A (en) | 2016-11-23 |
Family
ID=58063705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510127377.8A Pending CN106138164A (en) | 2015-03-23 | 2015-03-23 | A kind of compound Chinese medicinal preparation with Adjust-blood lipid function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138164A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106563006A (en) * | 2017-01-24 | 2017-04-19 | 倪京满 | Traditional Chinese medicine compound preparation with anti-atherosclerosis function |
| CN112107665A (en) * | 2019-06-19 | 2020-12-22 | 广州中医药大学第一附属医院 | Turbidity-reducing and fat-reducing capsule |
| CN115887520A (en) * | 2022-11-18 | 2023-04-04 | 江苏德和生物科技有限公司 | A composition with auxiliary lipid-lowering effect, preparation method and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1398632A (en) * | 2002-08-13 | 2003-02-26 | 黄谷 | Blood fat-regulating medicine composition |
| CN101731599A (en) * | 2008-11-12 | 2010-06-16 | 柯宏 | Composition for preventing and treating cardiovascular and cerebrovascular diseases |
| CN102106895A (en) * | 2009-12-28 | 2011-06-29 | 安琪酵母股份有限公司 | Composition with function of regulating blood fat |
| CN102172373A (en) * | 2011-01-12 | 2011-09-07 | 涂传荣 | Traditional Chinese medicine preparation with blood fat reducing effect |
| CN103417601A (en) * | 2012-05-18 | 2013-12-04 | 北京北大维信生物科技有限公司 | Pharmaceutical composition capable of adjusting blood fat and applications thereof |
-
2015
- 2015-03-23 CN CN201510127377.8A patent/CN106138164A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1398632A (en) * | 2002-08-13 | 2003-02-26 | 黄谷 | Blood fat-regulating medicine composition |
| CN101731599A (en) * | 2008-11-12 | 2010-06-16 | 柯宏 | Composition for preventing and treating cardiovascular and cerebrovascular diseases |
| CN102106895A (en) * | 2009-12-28 | 2011-06-29 | 安琪酵母股份有限公司 | Composition with function of regulating blood fat |
| CN102172373A (en) * | 2011-01-12 | 2011-09-07 | 涂传荣 | Traditional Chinese medicine preparation with blood fat reducing effect |
| CN103417601A (en) * | 2012-05-18 | 2013-12-04 | 北京北大维信生物科技有限公司 | Pharmaceutical composition capable of adjusting blood fat and applications thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106563006A (en) * | 2017-01-24 | 2017-04-19 | 倪京满 | Traditional Chinese medicine compound preparation with anti-atherosclerosis function |
| CN112107665A (en) * | 2019-06-19 | 2020-12-22 | 广州中医药大学第一附属医院 | Turbidity-reducing and fat-reducing capsule |
| CN115887520A (en) * | 2022-11-18 | 2023-04-04 | 江苏德和生物科技有限公司 | A composition with auxiliary lipid-lowering effect, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101239112B (en) | Traditional Chinese medicine composition for regulating blood lipid and preparation method thereof | |
| CN102784363B (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method thereof | |
| CN103070880B (en) | Application of acanthopanax trifoliatus polysaccharide in preparing medicine for treating diabetes | |
| CN103127232A (en) | Total extract for mulberry leaf prescription as well as preparation and usage thereof | |
| CN104623201A (en) | Medicine for protecting liver, removing toxicity, reducing blood lipid and reducing blood sugar and application thereof | |
| CN102416148B (en) | Medicine for treating depression, and preparation method and application thereof | |
| CN106138164A (en) | A kind of compound Chinese medicinal preparation with Adjust-blood lipid function | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN101810337A (en) | Health food containing pseudo-ginseng and ganoderma lucidum and radix astragali | |
| CN102631494B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN107029074A (en) | A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver | |
| CN103520318A (en) | Traditional Chinese medicine composition of enhancing immune function and preparation method of composition | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN103202898B (en) | Traditional chinese medicine composition and preparation method thereof | |
| CN108771683A (en) | Treat Paeoniflorin/synephrine composition and its application of gastrointestinal dysfunction or intestinal irritable syndrome | |
| CN103495115B (en) | A kind of to the medicative medicated wine of diabetes tool | |
| CN103272146A (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN101468056B (en) | Chinese medicine preparation for treating enteritis, diarrhea, and red-white dysentery | |
| CN101317900A (en) | Traditional Chinese medicine composition for preventing and treating alcoholic liver injury and preparation method thereof | |
| CN104435772A (en) | Hawthorn-containing pharmaceutical composition for reducing blood fat | |
| CN104721414A (en) | Gynostemma pentaphylla lipid-lowering tea | |
| CN108524477A (en) | Treat synephrine composition and its application of gastrointestinal dysfunction or intestinal irritable syndrome | |
| CN102000303B (en) | Compound traditional Chinese medicine preparation for suppressing tumors | |
| CN104069149A (en) | Method for processing traditional Chinese medicine decoction piece by using bear gall as matrix | |
| CN103505507A (en) | Traditional Chinese medicine composition containing glossy ganoderma and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161123 |